Relay Therapeutics, Inc. (RLAY)
Largest Insider Buys in Sector
RLAY Stock Price History Chart
RLAY Stock Performance
About Relay Therapeutics, Inc.
Relay Therapeutics, Inc. operates as a clinical-stage precision medicines company. It engages in transforming the drug discovery process with an initial focus on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. The company's lead product candidates include RLY-4008, an oral small molecule inhibitor of fibroblast growth factor receptor 2 (FGFR2), which is in a first-in-human clinical trial for patients with advanced or metastatic FGFR2-altered solid tumors; RLY-2608, a lead mutant-PI3Ka …
Insider Activity of Relay Therapeutics, Inc.
Over the last 12 months, insiders at Relay Therapeutics, Inc. have bought $0 and sold $2.2M worth of Relay Therapeutics, Inc. stock.
On average, over the past 5 years, insiders at Relay Therapeutics, Inc. have bought $3.2M and sold $120.29M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 20,000 shares for transaction amount of $200,000 was made by Adams Brian (General Counsel) on 2020‑07‑20.
List of Insider Buy and Sell Transactions, Relay Therapeutics, Inc.
| 2024-10-29 | Sale | Chief Financial Officer | 2,300 0.0014% | $5.95 | $13,685 | -0.93% | ||
| 2024-10-28 | Sale | President, R&D | 2,688 0.0015% | $6.06 | $16,289 | 0.00% | ||
| 2024-10-28 | Sale | See remarks | 1,621 0.0009% | $6.06 | $9,823 | 0.00% | ||
| 2024-10-28 | Sale | Chief Legal Officer | 1,632 0.0009% | $6.06 | $9,890 | 0.00% | ||
| 2024-10-28 | Sale | Chief Financial Officer | 6,802 0.0038% | $6.06 | $41,220 | 0.00% | ||
| 2024-09-27 | Sale | President, R&D | 648 0.0005% | $7.51 | $4,866 | -15.01% | ||
| 2024-09-27 | Sale | See remarks | 245 0.0002% | $7.51 | $1,840 | -15.01% | ||
| 2024-09-27 | Sale | Chief Legal Officer | 295 0.0002% | $7.51 | $2,215 | -15.01% | ||
| 2024-09-27 | Sale | Chief Financial Officer | 6,457 0.0049% | $7.46 | $48,184 | -15.01% | ||
| 2024-07-31 | Sale | See remarks | 13,708 0.0102% | $8.19 | $112,269 | -2.44% | ||
| 2024-07-30 | Sale | See remarks | 15,128 0.0114% | $8.28 | $125,260 | -3.50% | ||
| 2024-07-29 | Sale | President, R&D | 2,698 0.0022% | $8.85 | $23,877 | -18.07% | ||
| 2024-07-29 | Sale | See remarks | 13,523 0.0106% | $8.54 | $115,543 | -18.07% | ||
| 2024-07-29 | Sale | Chief Legal Officer | 1,638 0.0013% | $8.85 | $14,496 | -18.07% | ||
| 2024-07-29 | Sale | Chief Financial Officer | 10,780 0.0085% | $8.56 | $92,316 | -18.07% | ||
| 2024-07-26 | Sale | President and CEO | 36,706 0.0281% | $9.07 | $332,923 | -24.61% | ||
| 2024-07-25 | Sale | President and CEO | 50,000 0.0381% | $9.16 | $458,000 | -25.55% | ||
| 2024-06-27 | Sale | President, R&D | 648 0.0005% | $6.26 | $4,056 | 0.00% | ||
| 2024-06-27 | Sale | See remarks | 245 0.0002% | $6.26 | $1,534 | 0.00% | ||
| 2024-06-27 | Sale | Chief Financial Officer | 9,373 0.007% | $6.24 | $58,493 | 0.00% |
Insider Historical Profitability
| Patel Sanjiv | President and CEO | 766130 0.4577% | $4.63 | 1 | 12 | <0.0001% |
| Adams Brian | Chief Legal Officer | 321907 0.1923% | $4.63 | 1 | 31 | <0.0001% |
| Murcko Mark | 996952 0.5956% | $4.63 | 1 | 1 | <0.0001% | |
| INGRAM DOUGLAS S | director | 25000 0.0149% | $4.63 | 1 | 0 | <0.0001% |
| Rubin Jami | director | 25000 0.0149% | $4.63 | 1 | 0 | <0.0001% |
Institutional Investor Ownership
| SoftBank Investment Advisers | $231.61M | 21.02 | 27.9M | 0% | +$0 | 2.29 | |
| The Vanguard Group | $98.07M | 8.9 | 11.82M | +10.94% | +$9.67M | <0.01 | |
| BlackRock | $81.31M | 7.38 | 9.8M | +2.33% | +$1.85M | <0.01 | |
| Casdin Capital | $61.62M | 5.59 | 7.42M | +0.48% | +$295,737.30 | 3.04 | |
| T. Rowe Price | $57.1M | 5.18 | 6.88M | -19.83% | -$14.12M | 0.01 |